CD36 as a double-edged sword in cancer
Immunology Letters · 2024-02 · 265 · 7-15
DOI: 10.1016/j.imlet.2023.12.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology Letters, 2024-02. Verfasst von Muwei Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Nijenborgh 7, Groni…. Hauptthemen laut MEDLINE: CD36 Antigens, Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Horizon 2020, ERC.
Abstract (Originalsprache)
The membrane protein CD36 is a lipid transporter, scavenger receptor, and receptor for the antiangiogenic protein thrombospondin 1 (TSP1). CD36 is expressed by cancer cells and by many associated cells including various cancer-infiltrating immune cell types. Thereby, CD36 plays critical roles in cancer, and it has been reported to affect cancer growth, metastasis, angiogenesis, and drug resistance. However, these roles are partly contradictory, as CD36 has been both reported to promote and inhibit cancer progression. Moreover, the mechanisms are also partly contradictory, because CD36 has been shown to exert opposite cellular effects such as cell division, senescence and cell death. This review provides an overview of the diverse effects of CD36 on tumor progression, aiming to shed light on its diverse pro- and anti-cancer roles, and the implications for therapeutic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Nijenborgh 7, Groningen, the Netherlands.
- Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Nijenborgh 7, Groningen, the Netherlands. Electronic address: g.van.den.bogaart@rug.nl.
Förderung
- European Research Council
- Horizon 2020
- ERC
Zitieren
APA
Jiang, M., Karsenberg, R., Bianchi, F., & van den Bogaart, G. (2024). CD36 as a double-edged sword in cancer. Immunology Letters, 265, 7-15. https://doi.org/10.1016/j.imlet.2023.12.002
Vancouver
Jiang M, Karsenberg R, Bianchi F, van den Bogaart G. CD36 as a double-edged sword in cancer. Immunology Letters. 2024;265:7-15. doi:10.1016/j.imlet.2023.12.002
BibTeX
@article{Jiang2024,
author = {Jiang, Muwei and Karsenberg, Renske and Bianchi, Frans and van den Bogaart, Geert},
title = {CD36 as a double-edged sword in cancer},
journal = {Immunology Letters},
year = {2024},
volume = {265},
pages = {7--15},
doi = {10.1016/j.imlet.2023.12.002}
}
EUVIMED